Sandra E. Dunn

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.
  2025 L1 73/100

1 assessed by us (0 reproduced) · 210 not yet assessed — every PubMed paper on record, linked below.

• RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia

  Nature Communications · 2025 · PMID 39820365
  L1 73/100
• Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice? ↗

  Cancers · 2025 · PMID 40075731
  not yet assessed
• Dauntless-1, a phase 2 clinical trial to evaluate PMD-026, a first-in-class pan-RSK inhibitor, combined with fulvestrant to overcome resistance to CDK4/6 inhibitors in advanced or metastatic HR+/HER2- breast cancer. ↗

  Journal of Clinical Oncology · 2025
  not yet assessed
• Abstract P4-08-27: PMD-026, a First-in-Class RSK Inhibitor, Overcomes Acquired Resistance to CDK4/6 Inhibitors or Aromatase Inhibitors in HR+/HER2- Breast Cancer Preclinical Models ↗

  Clinical Cancer Research · 2025
  not yet assessed
• A qualitative assessment of patient journeys to a lipodystrophy diagnosis ↗

  Rare · 2025
  not yet assessed
• RSK1 dependency in FLT3-ITD acute myeloid leukemia ↗

  Blood Cancer Journal · 2024 · PMID 39592591
  not yet assessed
• Abstract PO3-29-04: Patient selection for high RSK2 expression is key for achieving improved PFS in metastatic breast cancer in the PMD-026 Phase 1/1b study ↗

  Cancer Research · 2024
  not yet assessed
• PENICILLIN ALLERGY AND ANTIBIOTIC STEWARDSHIP: TRAINING MEDICAL STUDENTS TO APPLY THE PEN-FAST TOOL ↗

  Annals of Allergy Asthma & Immunology · 2024
  not yet assessed
• Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion ↗

  Journal of Experimental & Clinical Cancer Research · 2023 · PMID 37464364
  not yet assessed
• Abstract P4-01-16: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor ↗

  Cancer Research · 2023
  not yet assessed
• RSK1 Is an Exploitable Dependency in Myeloid Malignancies ↗

  Blood · 2023
  not yet assessed
• Supplementary Slide 3 from Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 ↗

  2023
  not yet assessed
• Data from Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 ↗

  2023
  not yet assessed
• Data from Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 ↗

  2023
  not yet assessed
• Data from Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice ↗

  2023
  not yet assessed
• Data from Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice ↗

  2023
  not yet assessed
• Supplementary Slide 3 from Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-3 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Data from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  2023
  not yet assessed
• Supplementary Table 1 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  2023
  not yet assessed
• Data from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Data from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  2023
  not yet assessed
• Supplementary Table 1 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-3 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Supplementary Tables 1 - 5, Figures 1 - 6 from Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children ↗

  2023
  not yet assessed
• Supplementary Figure Legend from Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children ↗

  2023
  not yet assessed
• Data from Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Data from Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i><sup>6</sup>-methylguanine-DNA methyltransferase ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival ↗

  2023
  not yet assessed
• Supplementary Methods and Materials, Figures 1-6 from Y-Box Binding Protein-1 Induces the Expression of <i>CD44</i> and <i>CD49f</i> Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance ↗

  2023
  not yet assessed
• Supplementary Methods and Materials, Figures 1-6 from Y-Box Binding Protein-1 Induces the Expression of <i>CD44</i> and <i>CD49f</i> Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance ↗

  2023
  not yet assessed
• Supplementary Tables 1 - 5, Figures 1 - 6 from Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children ↗

  2023
  not yet assessed
• Supplementary Figure Legend from Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival ↗

  2023
  not yet assessed
• Supplementary Figure 3A from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 5A-D from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 3B from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 3C-D from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 2A-E from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 4A from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Table 2 from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 1C from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 4C-E from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Table 1 from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 1A-B from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 4B from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 3B from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 2A-E from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 1C from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 3A from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 3C-D from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 4A from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 4C-E from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 4B from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 1A-B from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Figure 5A-D from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Table 2 from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Supplementary Table 1 from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Data from Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival ↗

  2023
  not yet assessed
• Data from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Data from Y-Box Binding Protein-1 Induces the Expression of <i>CD44</i> and <i>CD49f</i> Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance ↗

  2023
  not yet assessed
• Data from Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children ↗

  2023
  not yet assessed
• Data from Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival ↗

  2023
  not yet assessed
• Data from Y-Box Binding Protein-1 Induces the Expression of <i>CD44</i> and <i>CD49f</i> Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance ↗

  2023
  not yet assessed
• Data from YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  2023
  not yet assessed
• Additional file 8 of Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion ↗

  Open MIND · 2023
  not yet assessed
• Abstract 5378: PMD-026, a first in class oral RSK inhibitor, demonstrates activity against hormone receptor positive breast cancer with acquired CDK4/6 inhibitor resistance ↗

  Cancer Research · 2022
  not yet assessed
• Abstract P5-17-12: First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients ↗

  Cancer Research · 2022
  not yet assessed
• Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review ↗

  Pediatric and Developmental Pathology · 2021 · PMID 33749384
  not yet assessed
• First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer. ↗

  Journal of Clinical Oncology · 2021
  not yet assessed
• Abstract 1038: PMD-026, a first in class oral RSK inhibitor, demonstrates synergy when combined with standard of care in breast cancer tumor models ↗

  Cancer Research · 2021
  not yet assessed
• Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients ↗

  Cancer Research · 2021
  not yet assessed
• Abstract 1218: Targeting B-RAF and checkpoint inhibitor resistant melanoma with RSK inhibitor PMD-026 in pre-clinical models ↗

  Cancer Research · 2021
  not yet assessed
• The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials ↗

  Expert Opinion on Investigational Drugs · 2020 · PMID 32869671
  not yet assessed
• Expression of Concern: Mechanisms underlying p53 regulation of <i>PIK3CA</i> transcription in ovarian surface epithelium and in ovarian cancer ↗

  Journal of Cell Science · 2020 · PMID 32917731
  not yet assessed
• Abstract P3-10-10: PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for triple negative breast cancer (TNBC) ↗

  Cancer Research · 2020
  not yet assessed
• First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer. ↗

  Journal of Clinical Oncology · 2020
  not yet assessed
• Dr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer ↗

  Expert Opinion on Investigational Drugs · 2020 · PMID 33070643
  not yet assessed
• Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells ↗

  Journal of Pediatric Hematology/Oncology · 2019 · PMID 30702467
  not yet assessed
• RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer ↗

  Expert Opinion on Therapeutic Targets · 2019 · PMID 31875730
  not yet assessed
• YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT ↗

  Molecular Cancer Research · 2018 · PMID 29743296
  not yet assessed
• PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions ↗

  Leukemia · 2017 · PMID 28050012
  not yet assessed
• Divergent clonal selection dominates medulloblastoma at recurrence ↗

  Nature · 2016 · PMID 26760213
  not yet assessed
• Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia ↗

  Oncology Letters · 2016 · PMID 28123588
  not yet assessed
• Stem Cell Signaling in the Heterogeneous Development of Medulloblastoma ↗

  2016
  not yet assessed
• Concise Review: Bullseye: Targeting Cancer Stem Cells to Improve the Treatment of Gliomas by Repurposing Disulfiram ↗

  Stem Cells · 2015 · PMID 25588723
  not yet assessed
• Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells ↗

  Oncotarget · 2015 · PMID 26011941
  not yet assessed
• EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study ↗

  Cancer · 2015 · PMID 25586788
  not yet assessed
• Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells ↗

  Oncotarget · 2015 · PMID 26512918
  not yet assessed
• 4. “Biphasic” histology is associated with the non-WNT/SHH molecular subtype of medulloblastoma ↗

  Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2015
  not yet assessed
• Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations ↗

  Nature Genetics · 2014 · PMID 24705254
  not yet assessed
• YB-1 Transforms Human Mammary Epithelial Cells Through Chromatin Remodeling Leading to the Development of Basal-Like Breast Cancer ↗

  Stem Cells · 2014 · PMID 24648416
  not yet assessed
• The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience ↗

  Child s Nervous System · 2014 · PMID 25391979
  not yet assessed
• Deep Sequencing Identifies <i>IDH1</i> R132S Mutation in Adult Medulloblastoma ↗

  Journal of Clinical Oncology · 2014 · PMID 24616312
  not yet assessed
• SOX2 IDENTIFIES THE TREATMENT-REFRACTORY STEM CELL POPULATION IN GROUP 2 MEDULLOBLASTOMA ↗

  Neuro-Oncology · 2014
  not yet assessed
• Targeting TKI-Insensitive CML Stem/Progenitor Cells By Effective Inhibition of a Novel PP2A-AHI-1-BCR-ABL-JAK2 Complex ↗

  Blood · 2014
  not yet assessed
• Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis ↗

  The Lancet Oncology · 2013 · PMID 24140199
  not yet assessed
• Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress ↗

  Nature Communications · 2013 · PMID 23877263
  not yet assessed
• Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children ↗

  Cancer Research · 2013 · PMID 24019381
  not yet assessed
• Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma ↗

  Pediatric Blood & Cancer · 2013 · PMID 23940083
  not yet assessed
• Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer ↗

  Oncogene · 2013 · PMID 23851501
  not yet assessed
• FoxG1 Interacts with Bmi1 to Regulate Self-Renewal and Tumorigenicity of Medulloblastoma Stem Cells ↗

  Stem Cells · 2013 · PMID 23592496
  not yet assessed
• Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1) ↗

  Oncotarget · 2013 · PMID 23593654
  not yet assessed
• Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities ↗

  Cell Communication and Signaling · 2013 · PMID 24103640
  not yet assessed
• Genomic imbalance of<i>HMMR/RHAMM</i>regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition ↗

  Oncotarget · 2013 · PMID 23328114
  not yet assessed
• Abstract 506: Targeting Y-box binding protein-1 (YB-1) overcomes drug resistance in triple-negative breast cancer. ↗

  Cancer Research · 2013
  not yet assessed
• Abstracts ↗

  Neuro-Oncology · 2013
  not yet assessed
• Abstract LB-214: Common genomic alterations in malignant peripheral nerve sheath tumors augment Aurora A activity and sensitize tumors to aurora kinase inhibitors. ↗

  Cancer Research · 2013
  not yet assessed
• BOARD OF SPEECH-LANGUAGE PATHOLOGY AND AUDIOLOGY

  2013
  not yet assessed
• Abstract A037: YB-1 transforms mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer ↗

  Molecular Cancer Research · 2013
  not yet assessed
• Abstract B065: The RSK/YB-1 pathway represents an opportunity for targeting TNBC and holds promise of treating metastases ↗

  Molecular Cancer Research · 2013
  not yet assessed
• Abstract 3552: Subgroup-specific pattern of recurrence in medulloblastoma. ↗

  Cancer Research · 2013
  not yet assessed
• YB-1: oncoprotein, prognostic marker and therapeutic target? ↗

  Biochemical Journal · 2012 · PMID 23216250
  not yet assessed
• Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide ↗

  Oncotarget · 2012 · PMID 23047041
  not yet assessed
• Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice ↗

  Stem Cells · 2012 · PMID 22415968
  not yet assessed
• Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells ↗

  Breast Cancer Research · 2012 · PMID 22309939
  not yet assessed
• Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-Box Binding Protein-1 in Triple-Negative Breast Cancers ↗

  Stem Cells · 2012 · PMID 22674792
  not yet assessed
• Medulloblastoma stem cells: where development and cancer cross pathways ↗

  Pediatric Research · 2012 · PMID 22430388
  not yet assessed
• MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition ↗

  Oncogene · 2012 · PMID 22249268
  not yet assessed
• Medulloblastoma stem cells: Modeling tumor heterogeneity ↗

  Cancer Letters · 2012 · PMID 22796365
  not yet assessed
• Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia ↗

  Blood · 2012
  not yet assessed
• Stem Cells in Brain Tumour Development and Therapy- Two-Sides of the Same Coin ↗

  Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2012 · PMID 22343146
  not yet assessed
• Abstract 811: VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme ↗

  Cancer Research · 2012
  not yet assessed
• YB-1 Is Activated by IL-7 and Is Overexpressed in Pediatric Pre-B Acute Lymphoblastic Leukemia ↗

  Blood · 2012
  not yet assessed
• Effect of VAL-083, a novel N7 alkylating agent, on growth of temolozomide-resistant primary adult glioblastoma multiforme (GBM) cells providing a new potential treatment option for GBM. ↗

  Journal of Clinical Oncology · 2012
  not yet assessed
• YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth ↗

  Cancer Research · 2011 · PMID 21730024
  not yet assessed
• YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification ↗

  Oncogene · 2011 · PMID 21423216
  not yet assessed
• YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention ↗

  Oncotarget · 2011 · PMID 21576761
  not yet assessed
• Abstracts from the 2011 BNOS Conference, June 29 - July 1, 2011, Homerton College, Cambridge ↗

  Neuro-Oncology · 2011
  not yet assessed
• Abstract LB-101: Y-box binding protein-1 (YB-1) inhibition triggers differentiation of normal and cancer stem cells from the brain ↗

  Cancer Research · 2011
  not yet assessed
• Y-Box Binding Protein-1 Induces the Expression of <i>CD44</i> and <i>CD49f</i> Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance ↗

  Cancer Research · 2010 · PMID 20332234
  not yet assessed
• The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells ↗

  Oncogene · 2010 · PMID 20802512
  not yet assessed
• Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1 ↗

  Oncogene · 2010 · PMID 20838384
  not yet assessed
• Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability ↗

  PLoS ONE · 2010 · PMID 20844753
  not yet assessed
• Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers ↗

  American Journal Of Pathology · 2010 · PMID 20228224
  not yet assessed
• Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer ↗

  Expert Reviews in Molecular Medicine · 2010 · PMID 20653987
  not yet assessed
• The promise and challenges of targeting RSK for the treatment of cancer ↗

  Expert Opinion on Therapeutic Targets · 2010 · PMID 21142801
  not yet assessed
• Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031 ↗

  Bone Marrow Transplantation · 2010 · PMID 20190833
  not yet assessed
• The role of Y-box binding protein-1 in collecting duct epithelial-mesenchymal transition

  Queensland's institutional digital repository (The University of Queensland) · 2010
  not yet assessed
• The Role of Y-Box Binding Protein-1 (YB-1) in Collecting Duct (CD) Epithelial-Mesenchymal Transition (EMT)

  2010
  not yet assessed
• Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells ↗

  Oncogene · 2009 · PMID 19151767
  not yet assessed
• The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1 ↗

  Oncogene · 2009 · PMID 19430491
  not yet assessed
• Nuclear detection of Y-boxprotein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer ↗

  BMC Cancer · 2009 · PMID 19930682
  not yet assessed
• Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent <i>O</i> 6-methylguanine-DNA methyltransferase ↗

  Molecular Cancer Therapeutics · 2009 · PMID 19996271
  not yet assessed
• Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas ↗

  Molecular Cancer Therapeutics · 2009 · PMID 19887553
  not yet assessed
• A Novel Therapeutic Approach of Suicide Gene/prodrug Therapy by Human Tumor-tropic Genetically Engineered Stem Cells expressing Suicide Genes to Selectively Target Ovarian and Breast Malignancies

  한국실험동물학회 학술발표대회 논문집 · 2009
  not yet assessed
• Who's missing: where's the consumer? ↗

  Elsevier eBooks · 2009
  not yet assessed
• Contributors ↗

  Elsevier eBooks · 2009
  not yet assessed
• Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival ↗

  Cancer Research · 2008 · PMID 19074892
  not yet assessed
• Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells ↗

  Breast Cancer Research · 2008 · PMID 19036157
  not yet assessed
• Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes ↗

  Breast Cancer Research · 2008 · PMID 18925950
  not yet assessed
• Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice ↗

  Cancer Research · 2008 · PMID 18974106
  not yet assessed
• Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer ↗

  Journal of Cell Science · 2008 · PMID 18270270
  not yet assessed
• Targeting Y-box binding protein-1 (YB-1) in Her-2 over-expressing breast cancer cells induces apoptosis via the signal transducer and activator or transcription-3 (STAT3) pathway and suppresses tumor growth.

  Clinical Cancer Research · 2008
  not yet assessed
• THE TRANSCRIPTION FACTOR Y-BOX BINDING PROTEIN-1 (YB-1) INDUCES EXPRESSION OF THE PIK3CA ONCOGENE LEADING TO INCREASED INVASION OFBASAL-LIKE BREAST CARCINOMA CELLS ↗

  Clinical and investigative medicine · 2008
  not yet assessed
• Y-box binding protein-1 (YB-1) serine 102 is a downstream target of p90 ribosomal S6 kinase in breast cancer cells

  Clinical Cancer Research · 2008
  not yet assessed
• Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors ↗

  Journal of Clinical Oncology · 2007 · PMID 17401009
  not yet assessed
• Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy ↗

  Breast Cancer Research · 2007 · PMID 17875215
  not yet assessed
• YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression. ↗

  PubMed · 2007 · PMID 23641145
  not yet assessed
• The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor ↗

  Molecular Pharmacology · 2007 · PMID 17595327
  not yet assessed
• Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK). ↗

  PubMed · 2007 · PMID 23645983
  not yet assessed
• Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 ↗

  Cancer Research · 2006 · PMID 16651443
  not yet assessed
• Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival ↗

  Cancer Research · 2006 · PMID 16397254
  not yet assessed
• Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor ↗

  Molecular Pharmacology · 2006 · PMID 16887935
  not yet assessed
• The Highly Conserved Family of <i>Tetrahymena thermophila</i> Chromosome Breakage Elements Contains an Invariant 10-Base-Pair Core ↗

  Eukaryotic Cell · 2006 · PMID 16607024
  not yet assessed
• Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells ↗

  Oncogene · 2005 · PMID 15806160
  not yet assessed
• Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours ↗

  Breast Cancer Research · 2005 · PMID 16168126
  not yet assessed
• Celecoxib Inhibits Urokinase-Type Plasminogen Activator (uPA) Production in MDA-MB-231 Breast Cancer Cells ↗

  Breast Cancer Research and Treatment · 2005 · PMID 16172791
  not yet assessed
• Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma ↗

  Clinical Cancer Research · 2004 · PMID 15448001
  not yet assessed
• Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival ↗

  Cancer Research · 2004 · PMID 14729636
  not yet assessed
• Role of IGF-1R in Mediating Breast Cancer Invasion and Metastasis ↗

  Breast Disease · 2003 · PMID 15687676
  not yet assessed
• 2. Survival Impact of HER-2/Neu, Cox-2, Urokinase Plasminogen Activator (upa), Cytokeratin 17/5,6 and other Markers with Long-Term Outcome of Early Breast Cancer. Report from the British Columbia Tissue Micro-Array Project (BCTMAP) ↗

  Breast Cancer Research and Treatment · 2003
  not yet assessed
• Insulin-Like Growth Factor-1 Inscribes a Gene Expression Profile for Angiogenic Factors and Cancer Progression in Breast Epithelial Cells ↗

  Neoplasia · 2002 · PMID 11988840
  not yet assessed
• Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. ↗

  PubMed · 2001 · PMID 11245436
  not yet assessed
• Gene expression profiling of normal breast epithelial cells following treatment with insulin-like growth factor I ↗

  Nature Genetics · 2001
  not yet assessed
• Insulin-like growth factor I stimulate angiogenesis and the production of vascular endothelial growth factor ↗

  Growth Hormone & IGF Research · 2000 · PMID 10984289
  not yet assessed
• The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: A new avenue for breast cancer therapy ↗

  Molecular Carcinogenesis · 2000 · PMID 10642432
  not yet assessed
• ACC guidelines for authors ↗

  Australian Critical Care · 2000
  not yet assessed
• Insulin-Like Growth Factor-I: a Key Regulator of Human Cancer Risk? ↗

  JNCI Journal of the National Cancer Institute · 1999 · PMID 10203270
  not yet assessed
• ACC guidelines for authors ↗

  Australian Critical Care · 1999
  not yet assessed
• ACC guidelines for authors ↗

  Australian Critical Care · 1999
  not yet assessed
• A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. ↗

  PubMed · 1998 · PMID 9699666
  not yet assessed
• Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo. ↗

  PubMed · 1998 · PMID 9568108
  not yet assessed
• ACC guidelines for authors ↗

  Australian Critical Care · 1998
  not yet assessed
• ACC guidelines for authors ↗

  Australian Critical Care · 1998
  not yet assessed
• ACC guidelines for authors ↗

  Australian Critical Care · 1998
  not yet assessed
• Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. ↗

  PubMed · 1997 · PMID 9354418
  not yet assessed
• In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks ↗

  Antimicrobial Agents and Chemotherapy · 1997 · PMID 9333028
  not yet assessed
• Overexpression of a p -glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks ( Marmota monax ) ↗

  Hepatology · 1996 · PMID 8666315
  not yet assessed
• Woodchuck p-glycoprotein found in virus-induced hepatocellular carcinomas binds anticancer drugs ↗

  Cancer Letters · 1996 · PMID 9018098
  not yet assessed
• ACC guidelines for authors ↗

  Australian Critical Care · 1996
  not yet assessed
• ACC guidelines for authors ↗

  Australian Critical Care · 1996
  not yet assessed
• Hypocholesterolemic properties of plant indoles ↗

  Biochemical Pharmacology · 1994 · PMID 8304980
  not yet assessed
• Effect of the plant compound indole-3-carbinol on hepatic cholesterol homoeostasis ↗

  Food and Chemical Toxicology · 1994 · PMID 8045476
  not yet assessed
• Leucocytes and leucopoietic capacity in thermally acclimated goldfish, <i>Carassim auratus</i> L. ↗

  Journal of Fish Biology · 1989
  not yet assessed